Publications dans lesquelles il/elle collabore avec Manuel Hidalgo Medina (20)

2017

  1. Clinical validation of prospective liquid biopsy monitoring in patients with wild-type RAS metastatic colorectal cancer treated with FOLFIRI-cetuximab

    Oncotarget, Vol. 8, Núm. 21, pp. 35289-35300

  2. Consensus guidelines for diagnosis, treatment and follow-up of patients with pancreatic cancer in Spain

    Clinical and Translational Oncology, Vol. 19, Núm. 6, pp. 667-681

2016

  1. Phase II trial of target-guided personalized chemotherapy in first-line metastatic colorectal cancer

    American Journal of Clinical Oncology: Cancer Clinical Trials, Vol. 39, Núm. 3, pp. 236-242

2015

  1. SPARC expression did not predict efficacy of nab-paclitaxel plus gemcitabine or gemcitabine alone for metastatic pancreatic cancer in an exploratory analysis of the phase III MPACT trial

    Clinical Cancer Research, Vol. 21, Núm. 21, pp. 4811-4818

2014

  1. A prospective pilot study of target-guided personalized chemotherapy with intensity-modulated radiotherapy in patients with early rectal cancer

    American Journal of Clinical Oncology: Cancer Clinical Trials, Vol. 37, Núm. 2, pp. 117-121

  2. Accurate identification of ALK positive lung carcinoma patients: Novel FDA-cleared automated fluorescence in situ hybridization scanning system and ultrasensitive immunohistochemistry

    PLoS ONE, Vol. 9, Núm. 9

  3. Integrated next-generation sequencing and avatar mouse models for personalized cancer treatment

    Clinical Cancer Research, Vol. 20, Núm. 9, pp. 2476-2484

  4. Reply: Comments on Stromal disrupting effects of nab-paclitaxel in pancreatic cancer

    British Journal of Cancer

2013

  1. Level of HER2 gene amplification predicts response and overall survival in her2-positive advanced gastric cancer treated with trastuzumab

    Journal of Clinical Oncology, Vol. 31, Núm. 35, pp. 4445-4452

  2. Lung adenocarcinoma in the era of targeted therapies: Histological classification, sample prioritization, and predictive biomarkers

    Clinical and Translational Oncology, Vol. 15, Núm. 7, pp. 503-508

  3. Stromal disrupting effects of nab-paclitaxel in pancreatic cancer

    British Journal of Cancer, Vol. 109, Núm. 4, pp. 926-933

  4. The ALK translocation in advanced non-small-cell lung carcinomas: Preapproval testing experience at a single cancer centre

    Histopathology, Vol. 62, Núm. 4, pp. 609-616

2012

  1. A comparison of EGFR mutation testing methods in lung carcinoma: Direct sequencing, real-time PCR and immunohistochemistry

    PLoS ONE, Vol. 7, Núm. 8

  2. HER2/neu testing for anti-HER2-based therapies in patients with unresectable and/or metastatic gastric cancer

    Journal of Clinical Pathology, Vol. 65, Núm. 8, pp. 751-757

2011

  1. Hybridization for human epidermal growth factor receptor 2 testing in gastric carcinoma: A comparison of fluorescence in-situ hybridization with a novel fully automated dual-colour silver in-situ hybridization method

    Histopathology, Vol. 59, Núm. 1, pp. 8-17

2010

  1. A combination of DR5 agonistic monoclonal antibody with gemcitabine targets pancreatic cancer stem cells and results in long-term disease control in human pancreatic cancer model

    Molecular Cancer Therapeutics, Vol. 9, Núm. 9, pp. 2582-2592

  2. A commercial real-time PCR kit provides greater sensitivity than direct sequencing to detect KRAS mutations: A morphology-based approach in colorectal carcinoma

    Journal of Molecular Diagnostics, Vol. 12, Núm. 3, pp. 292-299

2009

  1. A direct pancreatic cancer xenograft model as a platform for cancer stem cell therapeutic development

    Molecular Cancer Therapeutics, Vol. 8, Núm. 2, pp. 310-314

  2. Efficacy and pharmacodynamic effects of bosutinib (SKI-606), a Src/Abl inhibitor, in freshly generated human pancreas cancer xenografts

    Molecular Cancer Therapeutics, Vol. 8, Núm. 6, pp. 1484-1493

2008

  1. Antitumor activity and molecular effects of the novel heat shock protein 90 inhibitor, IPI-504, in pancreatic cancer

    Molecular Cancer Therapeutics, Vol. 7, Núm. 10, pp. 3275-3284